AML1 iso8 Forms the heterodimeric complex core-binding factor (CBF) with CBFB. RUNX members modulate the transcription of their target genes through recognizing the core consensus binding sequence 5'-TGTGGT-3', or very rarely, 5'-TGCGGT-3', within their regulatory regions via their runt domain, while CBFB is a non-DNA-binding regulatory subunit that allosterically enhances the sequence-specific DNA-binding capacity of RUNX. The heterodimers bind to the core site of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL3 and GM-CSF promoters. Essential for the development of normal hematopoiesis. Acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the BLK promoter. Inhibits KAT6B-dependent transcriptional activation. Involved in lineage commitment of immature T cell precursors. CBF complexes repress ZBTB7B transcription factor during cytotoxic (CD8+) T cell development. They bind to RUNX-binding sequence within the ZBTB7B locus acting as transcriptional silencer and allowing for cytotoxic T cell differentiation. CBF complexes binding to the transcriptional silencer is essential for recruitment of nuclear protein complexes that catalyze epigenetic modifications to establish epigenetic ZBTB7B silencing. Controls the anergy and suppressive function of regulatory T-cells (Treg) by associating with FOXP3. Activates the expression of IL2 and IFNG and down-regulates the expression of TNFRSF18, IL2RA and CTLA4, in conventional T-cells. Positively regulates the expression of RORC in T-helper 17 cells. Isoform AML-1G shows higher binding activities for target genes and binds TCR-beta-E2 and RAG-1 target site with threefold higher affinity than other isoforms. It is less effective in the context of neutrophil terminal differentiation. Isoform AML-1L interferes with the transactivation activity of RUNX1. Expressed in all tissues examined except brain and heart. Highest levels in thymus, bone marrow and peripheral blood. 11 alternatively spliced human isoforms have been reported. Note: This description may include information from UniProtKB.
Protein type: DNA-binding; Oncoprotein; Transcription factor
Chromosomal Location of Human Ortholog: 21q22.12
Cellular Component:  core-binding factor complex; cytosol; intracellular membrane-bounded organelle; nucleoplasm; nucleus
Molecular Function:  ATP binding; DNA-binding transcription activator activity, RNA polymerase II-specific; DNA-binding transcription factor activity, RNA polymerase II-specific; protein binding; RNA polymerase II proximal promoter sequence-specific DNA binding; RNA polymerase II regulatory region sequence-specific DNA binding; transcription regulatory region DNA binding
Biological Process:  hematopoietic stem cell proliferation; hemopoiesis; negative regulation of CD4-positive, alpha-beta T cell differentiation; negative regulation of gene expression; negative regulation of transcription by RNA polymerase II; peripheral nervous system neuron development; positive regulation of angiogenesis; positive regulation of CD8-positive, alpha-beta T cell differentiation; positive regulation of granulocyte differentiation; positive regulation of interleukin-2 production; positive regulation of transcription by RNA polymerase II; positive regulation of transcription, DNA-templated; regulation of B cell receptor signaling pathway; regulation of bicellular tight junction assembly; regulation of cytokine-mediated signaling pathway; regulation of hematopoietic stem cell differentiation; regulation of intracellular estrogen receptor signaling pathway; regulation of keratinocyte differentiation; regulation of megakaryocyte differentiation; regulation of myeloid cell differentiation; regulation of regulatory T cell differentiation; regulation of Wnt signaling pathway
Disease: Leukemia, Acute Myeloid; Platelet Disorder, Familial, With Associated Myeloid Malignancy
Reference #:  Q01196-8 (UniProtKB)
Alt. Names/Synonyms: Acute myeloid leukemia 1 protein; AML1; AML1 iso8; aml1 oncogene; AML1-EVI-1; AML1-EVI-1 fusion partner; AML1-EVI-1 fusion protein; AMLCR1; CBF-alpha-2; CBF2alpha; CBFA2; Core-binding factor subunit alpha-2; core-binding factor, runt domain, alpha subunit 2; EVI-1; mutant RUNX1; Oncogene AML-1; PEA2-alpha B; PEBP2-alpha B; PEBP2aB; PEBP2alpha; Polyomavirus enhancer-binding protein 2 alpha B subunit; runt related transcription factor 1; Runt-related transcription factor 1; RUNX family transcription factor 1; RUNX1; SL3-3 enhancer factor 1 alpha B subunit; SL3/AKV core-binding factor alpha B subunit
Gene Symbols: RUNX1
Molecular weight: 51,818 Da
Basal Isoelectric point: 8.89  Predict pI for various phosphorylation states
Protein-Specific Antibodies, siRNAs or Recombinant Proteins from Cell Signaling Technology® Total Proteins
Select Structure to View Below

AML1 iso8

Protein Structure Not Found.


Cross-references to other databases:  cBioPortal  |  Wikipedia  |  Pfam  |  UniProtKB  |  Entrez-Gene  |  GenPept  |  Ensembl Gene  |  Ensembl Protein